# A Single-Dose, Three-Way, Three-Sequence, Crossover BA Study of Azithromycin Oleogel

> **NCT05796362** · PHASE1 · COMPLETED · sponsor: **Brigham and Women's Hospital** · enrollment: 18 (actual)

## Conditions studied

- Infectious Disease
- Drug Effect
- Clinical Infection

## Interventions

- **DRUG:** Azithromycin Oleogel (Oral and Rectal)

## Key facts

- **NCT ID:** NCT05796362
- **Lead sponsor:** Brigham and Women's Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-08-08
- **Primary completion:** 2025-11-25
- **Final completion:** 2025-11-25
- **Target enrollment:** 18 (ACTUAL)
- **Last updated:** 2026-02-04

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05796362

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05796362, "A Single-Dose, Three-Way, Three-Sequence, Crossover BA Study of Azithromycin Oleogel". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT05796362. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*